Search the Studies

38 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number Title Protocol Status Min-Max Age Institute Keywords
001696-CSurveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)Recruitment has not started3-120 YearsNCI Malignant
001608-NPre-operative vs. Post-operative Stereotactic Radiosurgery for Operative Metastatic Brain TumorsParticipants currently recruited/enrolled18-99 YearsNINDSMalignant
001552-CPhase II Study of Enasidenib in IDH2-mutated Malignant Sinonasal and Skull Base TumorsParticipants currently recruited/enrolled18-120 YearsNCI Malignant
001549-CPhase II Evaluation of Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent in Subjects with BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage MesotheliomaParticipants currently recruited/enrolled18-120 YearsNCI Malignant
001534-CPhase I/II Trial of PLX038 in Primary Central Nervous System Tumors containing MYC or MYCN AmplificationsParticipants currently recruited/enrolled18-120 YearsNCI Malignant
001109-CDefining the Natural History of Squamous Cell Carcinoma in Fanconi AnemiaParticipants currently recruited/enrolled8-125 YearsNCI Malignant
000697-HU01 Cooperative Assessment of Late Effects for SCD Curative Therapies (COALESCE)Participants currently recruited/enrolled18-65 YearsNHLBIMalignant
000464-HEvaluation of Clonal Hematopoiesis in Patients with Sickle Cell Disease Receiving Curative TherapiesEnrolling by Invitation4-125 YearsNHLBIMalignant
000081-CA Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell SarcomaCompleted Study; data analyses ongoing2-125 YearsNCI Malignant
000059-CPhase I Study of Intratumor Injection of anti-Mesothelin Immunotoxin LMB-100 with Ipilimumab in Malignant MesotheliomaCompleted Study; data analyses ongoing18-120 YearsNCI Malignant
21-C-0024A Phase 2 Adaptive Study of Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple MyelomaNo longer recruiting/follow-up only18-125 YearsNCI Malignant
21-C-0021SARC037: A Phase I Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour Infusion in Ewing Sarcoma Patients in Combination with Low Dose Irinotecan and 3'Deoxy-3'-18F Fluorothymidine (18F-FLT) ImagingNo longer recruiting/follow-up only6-125 YearsNCI Malignant
21-C-0015Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment with Immune Checkpoint Inhibition (ICI) in Patients with Newly Diagnosed Glioblastoma or GliosarcomaParticipants currently recruited/enrolled18-125 YearsNCI Malignant
20-C-0023First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects with Metastatic Solid TumorsParticipants currently recruited/enrolled12-120 YearsNCI Malignant
19-C-0096Studying the Biology of IDH-mutant Gliomas via Longitudinal Observation of 2-Hydroxyglutarate (2-HG) Using MR SpectroscopyParticipants currently recruited/enrolled18-125 YearsNCI Malignant
19-C-0061A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath TumorsCompleted Study; data analyses ongoing12-125 YearsNCI Malignant
19-C-0016Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid TumorsParticipants currently recruited/enrolled0-125 YearsNCI Malignant
19-C-0006Phase II Trial Evaluating Nivolumab In Patients With IDH-Mutant Gliomas With And Without Hypermutator PhenotypeParticipants currently recruited/enrolled18-125 YearsNCI Malignant
17-C-0140Phase I/II Evaluation of Oral Decitabine/Tetrahydrouridine as Epigenetic Priming for Pembrolizumab Immune Checkpoint Blockade in Inoperable Locally Advanced or Metastatic Non-Small Cell Lung Cancers, Esophageal Carcinomas, or Pleural MesotheliomasCompleted Study; data analyses ongoing18-99 YearsNCI Malignant
17-C-0100Collection of Malignant Ascites, Pleural Fluid and Blood from Patients with Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI Malignant
17-C-0048Anti-CD30 CAR T Cells with Fully-human Binding Domains for Treating CD30-expressing Lymphomas Including Anaplastic Large Cell LymphomasCompleted Study; data analyses ongoing18-73 YearsNCI Malignant
17-C-0034A Randomized, Double Blind Phase II Trial of Surgery, Radiation Therapy Plus Temozolomide and Pembrolizumab with and without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)Completed Study; data analyses ongoing18-125 YearsNCI Malignant
16-C-0034A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior BevacizumabCompleted Study; data analyses ongoing18-125 YearsNCI Malignant
16-C-0011A Phase I-II Trial of Everolimus and Sorafenib in Patients with Recurrent High-Grade GliomasCompleted Study; data analyses ongoing18-125 YearsNCI Malignant
14-C-0163Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1: Clinical, Histopathologic, and Genomic AnalysisCompleted Study; data analyses ongoing10-125 YearsNCI Malignant
14-C-0004A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell LeukemiaNo longer recruiting/follow-up only18-125 YearsNCI Malignant
14-C-0001Phase II Study of Axitinib (AG-013736) with Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/ParagangliomaCompleted Study; data analyses ongoing18-125 YearsNCI Malignant
13-C-0202Tissue Procurement and Natural History Study of Patients with Malignant Mesothelioma and Other Mesothelin Expressing CancersParticipants currently recruited/enrolled2-125 YearsNCI Malignant
13-C-0152A Phase I Study of Autologous Activated Natural Killer (NK) Cells +/- rhIL15 in Children and Young Adults with Refractory Solid TumorsCompleted Study; data analyses ongoing2-29 YearsNCI Malignant
11-C-0190Collection of Tissue Blocks or Slides from Patients with CancerParticipants currently recruited/enrolled18-125 YearsNCI Malignant
10-DK-0102Clinical and Genetic Studies in Familial Non-Medullary Thyroid CancerParticipants currently recruited/enrolled7-90 YearsNIDDKMalignant
10-C-0056A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and LymphomasCompleted Study; data analyses ongoing18-125 YearsNCI Malignant
09-C-0242Prospective Comprehensive Molecular Analysis of Endocrine NeoplasmsParticipants currently recruited/enrolled4-125 YearsNCI Malignant
08-C-0079Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults with Neurofibromatosis Type 1No longer recruiting/follow-up only0-125 YearsNCI Malignant
06-C-0014Prospective Evaluation of Genetic and Epigenetic Alterations in Patients with Thoracic MalignanciesParticipants currently recruited/enrolled2-125 YearsNCI Malignant
00-CH-0160Clinical and Molecular Analysis of ACTH-Independent Steroid Hormone Production in Adrenocortical TissueCompleted Study; data analyses ongoing3-70 YearsNICHDMalignant
97-C-0147Collection of Serum and Tissue Samples from Patients with Biopsy-Proved or Suspected Malignant DiseasesParticipants currently recruited/enrolled2-125 YearsNCI Malignant
89-C-0086Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant DisordersParticipants currently recruited/enrolled2-125 YearsNCI Malignant
10 Center Drive,Bethesda, MD 20892 | Directions
Privacy Statement | Accessibility | Plain Language | FOIA | Disclaimer
Clinical Center | National Institutes of Health | HHS Vulnerability Disclosure | U.S. Department of Health and Human Services | USA.gov
NIH…Turning Discovery Into Health®